Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Seres Therapeutics, Inc.MCRB · Entity 7191 | See Remarks | February 15, 2026 | February 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Seres Therapeutics, Inc.
Report date February 15, 2026 · Filed February 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,557 |
Ending reported balance
After 2026-02-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-15 · Exercise / conversion · Acquired 231 · Balance 8,632 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Row 2 · 2026-02-15 · Sale · Disposed 75 · Balance 8,557 F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 5, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 531 |
Reported balance
After 2026-02-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-15 · Exercise / conversion · Disposed 133 · Balance 531 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 780 |
Reported balance
After 2026-02-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-15 · Exercise / conversion · Disposed 98 · Balance 780 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 5, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
F3: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
F4: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 27, 2023 Filed Nov 1, 2023 01:40 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 11,361 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-020079 · doc4.xml · derivative · entry 4 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,360 Underlying: Common Stock · 11,361 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date. F1 · shares: On February 3, 2023, the reporting person was granted an award of 22,721 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 11,361 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 11,360 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date. F1 · derivative.exercise_date: On February 3, 2023, the reporting person was granted an award of 22,721 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 11,361 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 11,360 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date. F4 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date. Read SEC document |
| October 27, 2023 Filed Nov 1, 2023 01:40 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 11,361 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-020079 · doc4.xml · nonDerivative · entry 1 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,361 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On February 3, 2023, the reporting person was granted an award of 22,721 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 11,361 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 11,360 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date. Read SEC document |
| April 27, 2023 Filed Nov 1, 2023 01:40 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantRestricted Stock Units · Derivative | 22,721 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-020079 · doc4.xml · derivative · entry 3 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,721 Underlying: Common Stock · 22,721 shares Expires not disclosed F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date. F1 · shares: On February 3, 2023, the reporting person was granted an award of 22,721 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 11,361 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 11,360 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date. F1 · derivative.exercise_date: On February 3, 2023, the reporting person was granted an award of 22,721 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 11,361 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 11,360 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date. F4 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date. Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 22:43 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (Right to Buy) · Derivative | 85,000 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0000899243-23-004200 · doc4.xml · derivative · entry 3 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2033-02-02 F4 · derivative.exercise_date: The option will vest as to 25% of the shares on February 3, 2024. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 22:43 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantRestricted Stock Units · Derivative | 85,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-004200 · doc4.xml · derivative · entry 2 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units will vest and settle as to 100% of the restricted stock units on August 3, 2024. F3 · derivative.expiration_date: The restricted stock units will vest and settle as to 100% of the restricted stock units on August 3, 2024. Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 22:43 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantRestricted Stock Units · Derivative | 42,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-004200 · doc4.xml · derivative · entry 1 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,500 Underlying: Common Stock · 42,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. F2 · derivative.expiration_date: The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. Read SEC document |
| February 04, 2022 Filed Feb 9, 2022 02:30 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $7.38 | $0.00 |
DisclosureSEC source: 0000899243-22-005319 · doc4.xml · derivative · entry 1 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2032-02-03 F1 · derivative.exercise_date: The option will vest as to 25% of the shares on February 4, 2023. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 23:51 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $26.34 | $0.00 |
DisclosureSEC source: 0000899243-21-005247 · doc4.xml · derivative · entry 1 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2031-02-03 F1 · derivative.exercise_date: The option will vest as to 25% of the shares on February 4, 2022. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document |
| June 29, 2020 Filed Jul 1, 2020 20:07 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $4.67 | $0.00 |
DisclosureSEC source: 0000899243-20-018111 · doc4.xml · derivative · entry 1 Young Teresa L. · CIK 0001814656 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2030-06-28 F1 · derivative.exercise_date: The option will vest as to 25% of the shares on June 29, 2021. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.